Survival analysis of breast cancer in patients with HER2/neu+, ER-, PR-: a retrospective cohort study

被引：0
|
作者：
Babaee, Ebrahim [1 ,2 ]
Nafissi, Nahid [3 ]
Amani, Paria [3 ]
Hamidabad, Negin Mahmoudi [3 ]
Negahi, Alireza [3 ]
Shojaee, Leyla [3 ]
Tayefi, Batool [2 ]
机构：
[1] Iran Univ Med Sci, Vaccine Res Ctr, Tehran, Iran
[2] Iran Univ Med Sci, Psychosocial Hlth Res Inst, Prevent Med & Publ Hlth Res Ctr, Sch Med,Community & Family Med Dept, Tehran, Iran
[3] Iran Univ Med Sci, Breast Hlth & Canc Res Ctr, Rasool Akram Med Complex Clin Res Dev Ctr RCRDC, Tehran, Iran
来源：
BREAST CANCER MANAGEMENT | 2023年 / 12卷 / 03期
关键词：
biomarker; breast cancer; estrogen receptor; HER2/neu; progesterone receptor; LYMPH-NODE METASTASES; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; PROGNOSTIC-FACTORS; SYSTEMIC THERAPY; FOLLOW-UP; HER2; TRASTUZUMAB; EXPRESSION; CARCINOMA;
D O I：
10.2217/bmt-2023-0015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: We aimed to study the characteristics of the breast cancer patients with positive HER2/neu+, ER- and PR- receptors. Methods: 119 patients with breast cancer were included in this retrospective cohort study from 2006 to 2016. The overall and disease-free survival were evaluated. Results: Most prevalent type of tumor was IDC, grade III cancer and stage II. Recurrence/metastasis occurred in 18.49%. Most common sites of metastasis were lungs and liver. Total mortality rate was 10.92%. Overall and disease-free survival times were 40.04 and 22.29 months, respectively. The median survival time was about 118 months. Conclusion: Breast cancers with positive HER2/neu and negative estrogen and progesterone receptors had low overall and disease-free survival rates compared with ER+/PR+/HER2- tumors.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study
    Poorolajal, Jalal
    Nafissi, Nahid
    Akbari, Mohammad Esmaeil
    Mahjub, Hossein
    Esmailnasab, Nader
    Babaee, Ebrahim
    ARCHIVES OF IRANIAN MEDICINE, 2016, 19 (10) : 680 - 686
  • [2] Breast Carcinoma With Chondroid Differentiation: A Clinicopathologic Study of 21 Triple Negative (ER-, PR-, Her2/neu-) Cases
    Gwin, Katja
    Wheeler, Darren T.
    Bossuyt, Veerle
    Tavassoli, Fattaneh A.
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2010, 18 (01) : 27 - 35
  • [3] The Association between ER, PR, HER2, and ER-/PR plus Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database
    Shao, Hong Yu
    Hao, Bao Tan
    Gao, Feng Xiao
    BREAST JOURNAL, 2023, 2023
  • [4] Comparison of the sensitivity to endocrine therapy of PR plus /ER- patients and ER plus /PR- patients with HER2+breast cancer
    Hao, X.
    Liu, Y.
    Hui, R.
    Zhang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] EFFECTS OF RESVERATROL ON TRIPLE NEGATIVE (ER-, PR-, HER2-) BREAST CANCER CELLS
    Mangum, Carla
    Cameron, Joseph A.
    Herbert, Brittney-Shea
    FASEB JOURNAL, 2008, 22
  • [6] Is Expression or Activation of Src Kinase Associated with Cancer-Specific Survival in ER-, PR- and HER2-Negative Breast Cancer Patients?
    Elsberger, Beatrix
    Tan, Bingchao A.
    Mitchell, Thomas J.
    Brown, Sylvia B. F.
    Mallon, Elizabeth A.
    Tovey, Sian M.
    Cooke, Timothy G.
    Brunton, Valerie G.
    Edwards, Joanne
    AMERICAN JOURNAL OF PATHOLOGY, 2009, 175 (04): : 1389 - 1397
  • [7] Factors Influencing Lymph Node Positivity in HER2/neu+ Breast Cancer Patients
    Englander, Katherine
    Chintapally, Neha
    Gallagher, Julia
    Elleson, Kelly
    Sun, Weihong
    Whiting, Junmin
    Laronga, Christine
    Lee, Marie Catherine
    CURRENT ONCOLOGY, 2023, 30 (03) : 2825 - 2833
  • [8] Quantifying the relative value of drug therapy options in HER2+, ER-/PR- breast cancer
    Whang, John
    Steinkellner, Amy R.
    Borne, Jane M.
    Piana, Elizabeth N.
    Wong, Winston
    Aubert, Ronald E.
    Selby, Norman C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer
    Radojicic, Jelena
    Zaravinos, Apostolos
    Vrekoussis, Thomas
    Kafousi, Maria
    Spandidos, Demetrios A.
    Stathopoulos, Efstathios N.
    CELL CYCLE, 2011, 10 (03) : 507 - 517
  • [10] Comparison of patients with "triple negative" breast cancer (ER-, PR-, HER2-) in a cohort of 1052 patients treated in a single institution between 1999 and 2007
    Kantelhardt, E. J.
    Pauli, N.
    Grosse, R.
    Vetter, A.
    Holzhausen, H. J.
    Strauss, H. G.
    Thomssen, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S255 - S255
12345